lestaurtinib has been researched along with Adenocarcinoma in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (75.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Berlin, J; Chan, E; Holen, KD; Lockhart, AC; Mulkerin, D; Rothenberg, M; Thomas, J | 1 |
| Angeles, T; Dionne, CA; George, DJ; Isaacs, JT; Jani, J; Lamb, J; Murakata, C | 1 |
| Dionne, CA; Klein-Szanto, AJ; Miknyoczki, SJ; Ruggeri, BA | 1 |
| Chang, H; Dionne, CA; Klein-Szanto, A; Miknyoczki, SJ; Ruggeri, BA | 1 |
1 trial(s) available for lestaurtinib and Adenocarcinoma
| Article | Year |
|---|---|
A phase I trial of CEP-701 + gemcitabine in patients with advanced adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carbazoles; Deoxycytidine; Drug Administration Schedule; Drug Interactions; Female; Furans; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms | 2008 |
3 other study(ies) available for lestaurtinib and Adenocarcinoma
| Article | Year |
|---|---|
Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555).
Topics: Adenocarcinoma; Administration, Oral; Androgens; Animals; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Carbazoles; Combined Modality Therapy; Drug Screening Assays, Antitumor; Drug Synergism; Furans; Indoles; Injections, Subcutaneous; Leuprolide; Male; Neoplasm Proteins; Neoplasm Transplantation; Neoplasms, Hormone-Dependent; Orchiectomy; Prostatic Neoplasms; Proto-Oncogene Proteins; Rats; Receptor Protein-Tyrosine Kinases; Receptor, trkA; Receptors, Nerve Growth Factor | 1999 |
The novel Trk receptor tyrosine kinase inhibitor CEP-701 (KT-5555) exhibits antitumor efficacy against human pancreatic carcinoma (Panc1) xenograft growth and in vivo invasiveness.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Carbazoles; Enzyme Inhibitors; Female; Furans; Humans; Indoles; Injections, Subcutaneous; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Structure; Neoplasm Invasiveness; Neoplasm Transplantation; Pancreatic Neoplasms; Rats; Receptor Protein-Tyrosine Kinases; Trachea | 1999 |
The Trk tyrosine kinase inhibitor CEP-701 (KT-5555) exhibits significant antitumor efficacy in preclinical xenograft models of human pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Body Weight; Carbazoles; Drug Screening Assays, Antitumor; Female; Furans; Humans; Immunohistochemistry; Indoles; Mice; Mice, Nude; Neoplasm Invasiveness; Neoplasm Transplantation; Pancreatic Neoplasms; Rats; Receptor, trkA; Time Factors; Trachea; Treatment Outcome; Tumor Cells, Cultured | 1999 |